An analysis of the potential impact of pneumococcal conjugate vaccine (PCV) in India found that introducing PCV vaccine will protect the population from potentially catastrophic health expenditures due to treatment and hospitalizations for pneumococcal disease – saving an estimated $49-63 million in out-of-pocket expenditures each year, depending on the assumed vaccination coverage rate. Financial protection will be greatest for the poorest households, with the poorest quintile is estimated to have the greatest savings in out-of-pocket expenditures of all wealth quintiles.
Full Citation:
Megiddo I, Klein E, Laxminarayan R. 2018. Potential impact of introducing the pneumococcal conjugate vaccine into national immunisation programmes: an economic epidemiological analysis using data from India. BMJ Global Health. 3(3).
Title of Article: Potential impact of introducing the pneumococcal conjugate vaccine into national immunisation programmes: an economic epidemiological analysis using data from India
Author(s): Megiddo I, Klein E, Laxminarayan R
Publication Year: 2018
Publication Name: BMJ Global Health
Publication Volume: 3(3)
Publication Source URL: https://pubmed.ncbi.nlm.nih.gov/29765775/
DOI (Digital Object Identifier): 10.1136/bmjgh-2017-000636
Topics: Economics & Return on Investment
Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia
Countries: India
WHO Regions: South-East Asia